Document is current
Any future updates will be listed below
-
Authors
Atzinger, Christopher
Arens, Hans-Jürgen
Neri, Luca
Arkossy, Otto
Garbelli, Mario
Jiletcovici, Alina
Snijder, Robert
Leyland, Kirsten
Khalife, Najib
Ali, Mahmood
Feuersenger, Astrid
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05530291 at ClinicalTrials.govDocuments that mention this clinical trial
Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study
https://doi.org/10.1007/s12325-024-03015-4
-
Funding
Funding for this research was provided by:
Astellas Pharma Global Development
- License Information
-
More Information
Article History
Received: 10 June 2024
Accepted: 26 September 2024
First Online: 25 November 2024
Declarations
:
: Hans-Jürgen Aren, Luca Neri, Astrid Feuersenger, Mario Garbelli and Otto Arkossy are employees of Fresenius Medical Care, contracted by Astellas Pharma Global Development Inc. to conduct the study. Hans-Jürgen Aren reports Fresenius Medical Care stock shares. Christopher Atzinger and Alina Jiletcovici are employees of Astellas Pharma Global Development Inc. Alina Jiletcovici reports Eli Lilly stock shares. Robert Snijder is an employee of Astellas Pharma Europe B.V. Kirsten Leyland, Najib Khalife and Mahmood Ali are employees of Astellas Pharma Europe Ltd.
: All data were pseudonymised and all patients provided written informed consent for access and secondary use of their pseudonymised clinical data for research purposes. According to the National Institutes of Health definition of human subject research, this study falls under the exempt human subjects research category [].
